HC Wainwright Reiterates Buy Rating for ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $94.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 54.10% from the company’s current price.

A number of other research analysts have also recently commented on the stock. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Raymond James increased their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. Truist Financial upped their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. Finally, Piper Sandler assumed coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.33.

ANI Pharmaceuticals Trading Down 1.2 %

Shares of ANI Pharmaceuticals stock opened at $61.00 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. ANI Pharmaceuticals has a 1 year low of $48.20 and a 1 year high of $70.81. The firm has a market cap of $1.28 billion, a PE ratio of -110.91 and a beta of 0.71. The company has a 50 day simple moving average of $58.57 and a two-hundred day simple moving average of $61.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter in the prior year, the firm earned $1.05 earnings per share. The firm’s revenue was up 12.5% on a year-over-year basis. Analysts expect that ANI Pharmaceuticals will post 3.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Innealta Capital LLC bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $65,000. Ridgewood Investments LLC purchased a new position in ANI Pharmaceuticals during the 2nd quarter valued at $85,000. SG Americas Securities LLC bought a new position in ANI Pharmaceuticals in the 1st quarter worth $106,000. O Shaughnessy Asset Management LLC purchased a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth about $218,000. Finally, XTX Topco Ltd bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $207,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.